Sierra Oncology

Sierra Oncology is a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer. The company harnesses its deep scientific expertise to identify compounds that target the root cause of disease. Sierra Oncology's team takes an evidence-based approach to understand the limitations of current treatments and explore new ways to change the cancer treatment paradigm. Sierra Oncology is transforming promise into patient impact.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GlaxoSmithKline

Britain's GlaxoSmithKline has agreed to buy California-based biopharmaceutical company Sierra Oncology in a deal valued at $1.9 billion, the companies said on Wednesday.

GSK to buy Sierra Oncology for $1.9 billion

LONDON--(BUSINESS WIRE)--GlaxoSmithKline plc (LSE/NYSE: GSK) and Sierra Oncology, Inc (Nasdaq: SRRA) today announced that the companies have entered into an agreement under which GSK will acquire Sierra Oncology, a California-based, late-stage biopharmaceutical company focused on targeted therapies for the treatment of rare forms of cancer, for $55 per share of common stock in cash representing an approximate total equity value of $1.9 billion (£1.5 billion). Myelofibrosis is a fatal cancer of

GSK Reaches Agreement to Acquire Late-Stage Biopharmaceutical Company Sierra Oncology For $1.9bn

SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced the company will participate in the 32nd Annual Oppenheimer Healthcare Conference being held virtually from March 15-17, 2022. President and Chief Executive Officer Stephen Dilly, MBBS, PhD, will provide an overview of the company on Tuesday, March 15, 2022, beginning at 3:20 pm ET. A replay of the presentat

Sierra Oncology to Participate in the Oppenheimer 32nd Annual Healthcare Conference

SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today reported its financial and operating results for the fourth quarter and fiscal year ended December 31, 2021. “Last year was a great year for Sierra. We accelerated timelines in the midst of a global pandemic to over enroll the pivotal MOMENTUM clinical trial, achieving statistical significance in the primary and all p

Sierra Oncology Reports 2021 Year End Results

SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (Nasdaq: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced that the underwriters of its previously announced underwritten public offering exercised in full their option to purchase 750,000 additional shares of common stock at a price of $27.00 per share, before deducting underwriting discounts and commissions. With this exercise, the aggregate gross proceeds to Sier

Sierra Oncology Announces Full Exercise of Underwriters' Option to Purchase Additional Shares

SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced the company will participate in the 4th Annual Guggenheim Oncology Conference being held virtually from February 9 – 11, 2022. President and Chief Executive Officer Stephen Dilly, MBBS, PhD, will participate in an analyst-moderated fireside chat on Thursday, February 10, 2022, at 12:00 pm ET. A replay of the

Sierra Oncology to Participate in Guggenheim Oncology Conference

SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (Nasdaq: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced the closing of its previously announced underwritten public offering of 4,074,075 shares of its common stock at a price to the public of $27.00 per share and, in lieu of shares of common stock, to a certain investor, pre-funded warrants to purchase up to 925,925 shares of common stock at a price to the publi

Sierra Oncology Announces Closing of Upsized Public Offering of $135.0 Million of Securities

Morphosys AG - ADR

Sierra Oncology got a boost on Monday, releasing some very strong data in relation to its lead asset Momelotinib.

Sierra Oncology's Strong Data In Myelofibrosis Challenges MorphoSys And Incyte

Sierra Oncology Inc has priced its underwritten public offering of 4.07 million shares at $27 per share and the pre-funded warrants at $26.999 per pre-funded warrant.

Sierra Oncology Raises $135M Via Equity To Fund Lead Program Development

SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced the company will participate in the 2022 B. Riley Securities Oncology Investor Conference being held virtually from January 27-28, 2022. President and Chief Executive Officer Stephen Dilly, MBBS, PhD, will provide an overview of the company at 2:30 pm ET on Friday, January 28, 2022. A replay of the presentat

Sierra Oncology to Present at B. Riley Securities Oncology Investor Conference

SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced the pricing of an upsized underwritten public offering of 4,074,075 shares of its common stock and, in lieu of shares of common stock, to a certain investor, pre-funded warrants to purchase up to 925,925 shares of common stock pursuant to its existing shelf registration statement. The shares of common stock

Sierra Oncology Announces Pricing of Upsized Public Offering of Securities

Positive results achieved in Phase 3 MOMENTUM study using momelotinib monotherapy for the treatment of myelofibrosis patients who are symptomatic and anemic. Momelotinib has a competitive advantage in that it's not a myelosuppressive agent, this means it provides superior efficacy and quality of life compared to currently approved therapies.

Sierra Oncology: Plenty Of Room To Trade Higher After Latest Myelofibrosis Data

SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced that it intends to offer and sell $100.0 million of shares of its common stock in an underwritten public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of

Sierra Oncology Announces Proposed Public Offering of Common Stock

Sierra Oncology Inc. (NASDAQ: SRRA) shares are up 50% after the company announced a term loan deal with Oxford Finance LLC and the release of positive topline results from the vital Phase III MOMENTUM study. The MOMENTUM study, a global double-blind, randomized trial, evaluated momelotinib in treating patients with myelofibrosis that are anemic and symptomatic […] La notizia Sierra Oncology surges 50%, here is the catalyst era stato segnalata su Invezz.

Sierra Oncology surges 50%, here is the catalyst

Sierra Oncology Inc (NASDAQ: SRRA) has entered into a term loan agreement with Oxford Finance LLC to support the commercial preparation and potential launch of momelotinib.  The Company estimates it held cash & cash equivalents of $104.7 million as of December 31, 2021.

Sierra Oncology Secures Debt Facility Of Up To $125M With Oxford Finance To Support Momelotinib Development

Sierra's long-shot blood cancer drug scores a big win in a pivotal-stage trial.

Why Sierra Oncology Stock Is On Fire Today

Sierra Oncology Inc (NASDAQ: SRRA) unveiled topline data for momelotinib in myelofibrosis patients who are symptomatic, anemic, and previously treated with an FDA-approved JAK inhibitor. With the new data in hand, Sierra now plans to submit a marketing application in Q2 FY22.

Sierra Oncology Shares Rally As Bone Marrow Cancer Candidate Hits Primary Goal

The stock price of Sierra Oncology Inc (NASDAQ: SRRA) increased by over 55% pre-market today. This is why it happened.

Sierra Oncology Stock (SRRA): Why The Price Substantially Went Up Today

SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced positive topline data from the pivotal Phase 3 MOMENTUM study—a global, randomized, double-blind clinical trial evaluating momelotinib (MMB) in myelofibrosis patients who are symptomatic and anemic and previously treated with an approved JAK inhibitor. The trial met all of its primary and key secondary endpo

Sierra Oncology Announces Momelotinib Achieved Statistically Significant Benefit on Symptoms, Anemia and Splenic Size in the Pivotal MOMENTUM Study for Myelofibrosis

SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced it has entered into a term loan agreement with Oxford Finance, LLC that is designed to primarily support the commercial preparation and potential launch of momelotinib, an investigational agent for the treatment of myelofibrosis, a rare form of blood cancer. The Company estimates it had cash and cash equival

Sierra Oncology Provides Financial Update to Support the Future Commercialization of Momelotinib

SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced the publication of a review article in the Journal of Hematology & Oncology that outlines the potential ability of momelotinib—a novel JAK1, JAK2 and ACVR1 / ALK2 inhibitor—to address the critical unmet need of anemia for myelofibrosis patients. Srdan Verstovsek, MD, PhD, Chief, Section for Myeloprolifer

Momelotinib Review Article Published in Journal of Hematology & Oncology Highlights Importance of Anemia Benefit for Myelofibrosis Patients

SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced it has shortened the timeline to the topline data readout of the MOMENTUM pivotal Phase 3 trial of momelotinib in patients with myelofibrosis. The company now expects to announce topline data by the end of January 2022. Assuming positive results, the company intends to file a New Drug Application (NDA) with

Sierra Oncology Updates Topline Data Timing for Pivotal Phase 3 Trial of Momelotinib in Myelofibrosis

SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced the company will participate in the 2022 HC Wainwright BioConnect Conference being held virtually from January 10-13, 2022. Stephen Dilly, MBBS, PhD, President and Chief Executive Officer of Sierra, will provide an overview of the company in a presentation that will be available on demand beginning at 7:00 a

Sierra Oncology to Present at HC Wainwright BioConnect Conference

ATLANTA--(BUSINESS WIRE)--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today announced data from new retrospective analyses of the Phase 3 SIMPLIFY studies demonstrate baseline ferritin differentially predicts Week 24 Transfusion Independence Response for momelotinib and ruxolitinib in patients with myelofibrosis. The data were presented at the 63rd American Society of Hematology (ASH) An

Sierra Oncology Reports Baseline Ferritin Differentially Predicts Week 24 Transfusion Independence Response in Myelofibrosis Patients

SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today announced it will host an analyst and investor event on Thursday, December 16, 2021, at 12:00 pm ET. The event will feature a presentation by Prithviraj Bose, MD, Department of Leukemia, MD Anderson Cancer Center, on the importance of treating anemia in myelofibrosis patients. Dr. Bose will also review

News for Sierra Oncology Stock (SRRA)